T-Lymphocytes, Cytotoxic

"T-Lymphocytes, Cytotoxic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.

Descriptor ID	D013602
MeSH Number(s)	A11.118.637.555.283.875 A11.118.637.555.567.550.500.200 A11.118.637.555.567.569.220.200 A11.118.637.555.567.569.500.200 A15.145.229.637.555.283.875 A15.145.229.637.555.567.550.500.200 A15.145.229.637.555.567.569.220.200 A15.145.229.637.555.567.569.500.200 A15.382.490.555.283.875 A15.382.490.555.567.550.500.200 A15.382.490.555.567.569.220.200 A15.382.490.555.567.569.500.200
Concept/Terms	T-Lymphocytes, Cytotoxic T-Lymphocytes, Cytotoxic Cytotoxic T-Lymphocyte T Lymphocytes, Cytotoxic T-Lymphocyte, Cytotoxic Cell-Mediated Lympholytic Cells Cell Mediated Lympholytic Cells Cell, Cell-Mediated Lympholytic Cell-Mediated Lympholytic Cell Cells, Cell-Mediated Lympholytic Lympholytic Cell, Cell-Mediated Lympholytic Cells, Cell-Mediated Cytotoxic T-Lymphocytes Cytotoxic T Lymphocytes TC2 Cells TC2 Cells Cell, TC2 Cells, TC2 TC2 Cell TC1 Cells TC1 Cells Cell, TC1 Cells, TC1 TC1 Cell

Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes, Cytotoxic".

Anatomy [A]
Cells [A11]
Blood Cells [A11.118]
Leukocytes [A11.118.637]
Leukocytes, Mononuclear [A11.118.637.555]
Cytokine-Induced Killer Cells [A11.118.637.555.283]
T-Lymphocytes, Cytotoxic [A11.118.637.555.283.875]
Lymphocytes [A11.118.637.555.567]
Lymphocyte Subsets [A11.118.637.555.567.550]
T-Lymphocyte Subsets [A11.118.637.555.567.550.500]
T-Lymphocytes, Cytotoxic [A11.118.637.555.567.550.500.200]
T-Lymphocytes [A11.118.637.555.567.569]
CD8-Positive T-Lymphocytes [A11.118.637.555.567.569.220]
T-Lymphocytes, Cytotoxic [A11.118.637.555.567.569.220.200]
T-Lymphocyte Subsets [A11.118.637.555.567.569.500]
T-Lymphocytes, Cytotoxic [A11.118.637.555.567.569.500.200]
Hemic and Immune Systems [A15]
Blood [A15.145]
Blood Cells [A15.145.229]
Leukocytes [A15.145.229.637]
Leukocytes, Mononuclear [A15.145.229.637.555]
Cytokine-Induced Killer Cells [A15.145.229.637.555.283]
T-Lymphocytes, Cytotoxic [A15.145.229.637.555.283.875]
Lymphocytes [A15.145.229.637.555.567]
Lymphocyte Subsets [A15.145.229.637.555.567.550]
T-Lymphocyte Subsets [A15.145.229.637.555.567.550.500]
T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.550.500.200]
T-Lymphocytes [A15.145.229.637.555.567.569]
CD8-Positive T-Lymphocytes [A15.145.229.637.555.567.569.220]
T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.569.220.200]
T-Lymphocyte Subsets [A15.145.229.637.555.567.569.500]
T-Lymphocytes, Cytotoxic [A15.145.229.637.555.567.569.500.200]
Immune System [A15.382]
Leukocytes [A15.382.490]
Leukocytes, Mononuclear [A15.382.490.555]
Cytokine-Induced Killer Cells [A15.382.490.555.283]
T-Lymphocytes, Cytotoxic [A15.382.490.555.283.875]
Lymphocytes [A15.382.490.555.567]
Lymphocyte Subsets [A15.382.490.555.567.550]
T-Lymphocyte Subsets [A15.382.490.555.567.550.500]
T-Lymphocytes, Cytotoxic [A15.382.490.555.567.550.500.200]
T-Lymphocytes [A15.382.490.555.567.569]
CD8-Positive T-Lymphocytes [A15.382.490.555.567.569.220]
T-Lymphocytes, Cytotoxic [A15.382.490.555.567.569.220.200]
T-Lymphocyte Subsets [A15.382.490.555.567.569.500]
T-Lymphocytes, Cytotoxic [A15.382.490.555.567.569.500.200]

Below are MeSH descriptors whose meaning is related to "T-Lymphocytes, Cytotoxic".

Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes, Cytotoxic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "T-Lymphocytes, Cytotoxic" by people in this website by year, and whether "T-Lymphocytes, Cytotoxic" was a major or minor topic of these publications.

Bar chart showing 117 publications over 29 distinct years, with a maximum of 11 publications in 1998

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	2	0	2
1994	2	4	6
1995	1	3	4
1996	3	2	5
1997	2	2	4
1998	5	6	11
1999	5	3	8
2000	3	4	7
2001	0	2	2
2002	6	2	8
2003	2	3	5
2004	2	4	6
2005	3	2	5
2006	3	1	4
2007	3	2	5
2008	3	1	4
2009	0	2	2
2010	0	4	4
2011	2	1	3
2012	1	2	3
2013	1	0	1
2014	2	0	2
2015	3	1	4
2016	1	1	2
2017	1	1	2
2018	1	2	3
2019	2	1	3
2021	1	0	1
2022	1	0	1

Below are the most recent publications written about "T-Lymphocytes, Cytotoxic" by people in Profiles.

Fierle JK, Abram-Saliba J, Atsaves V, Brioschi M, de Tiani M, Reichenbach P, Irving M, Coukos G, Dunn SM. A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors. Sci Rep. 2022 01 21; 12(1):1136.

View in: PubMed
Fierle JK, Brioschi M, de Tiani M, Wetterwald L, Atsaves V, Abram-Saliba J, Petrova TV, Coukos G, Dunn SM. Soluble trivalent engagers redirect cytolytic T?cell activity toward tumor endothelial marker 1. Cell Rep Med. 2021 08 17; 2(8):100362.

View in: PubMed
Kamga L, Gil A, Song I, Brody R, Ghersi D, Aslan N, Stern LJ, Selin LK, Luzuriaga K. CDR3a?drives selection of the immunodominant Epstein Barr virus (EBV) BRLF1-specific CD8 T cell receptor repertoire in primary infection. PLoS Pathog. 2019 11; 15(11):e1008122.

View in: PubMed
Koumantou D, Barnea E, Martin-Esteban A, Maben Z, Papakyriakou A, Mpakali A, Kokkala P, Pratsinis H, Georgiadis D, Stern LJ, Admon A, Stratikos E. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1). Cancer Immunol Immunother. 2019 Aug; 68(8):1245-1261.

View in: PubMed
Xiao Y, Muhuri M, Li S, Qin W, Xu G, Luo L, Li J, Letizia AJ, Wang SK, Chan YK, Wang C, Fuchs SP, Wang D, Su Q, Nahid MA, Church GM, Farzan M, Yang L, Wei Y, Desrosiers RC, Mueller C, Tai PW, Gao G. Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity. JCI Insight. 2019 05 21; 5.

View in: PubMed
Clayton KL, Collins DR, Lengieza J, Ghebremichael M, Dotiwala F, Lieberman J, Walker BD. Resistance of HIV-infected macrophages to CD8+ T lymphocyte-mediated killing drives activation of the immune system. Nat Immunol. 2018 05; 19(5):475-486.

View in: PubMed
Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018 04 11; 10(436).

View in: PubMed
Gatault P, Al-Hajj S, Noble J, Chevallier E, Piollet M, Forconi C, Gaudy-Graffin C, Thibault G, Miquelestorena-Standley E, Halimi JM, B?chler M, Lemoine R, Baron C. CMV-infected kidney grafts drive the expansion of blood-borne CMV-specific T cells restricted by shared class I HLA molecules via presentation on donor cells. Am J Transplant. 2018 08; 18(8):1904-1913.

View in: PubMed
Blevins S, Huseby ES. Killer T cells with a beta-flavi(r) for dengue. Nat Immunol. 2017 10 18; 18(11):1186-1188.

View in: PubMed
Rashighi M, Harris JE. Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin. 2017 Apr; 35(2):257-265.

View in: PubMed

People

Explore

Similar Concepts

Top Journals